Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.
Verzoni E, Cartenì G, Cortesi E, Giannarelli D, De Giglio A, Sabbatini R, Buti S, Rossetti S, Cognetti F, Rastelli F, Sobrero A, Turci D, Sternberg CN, Porta C, Cappuzzo F, Tortora G, Tassinari D, Panni S, Pazzola A, Surico G, Raimondi A, De Giorgi U, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program group.
Verzoni E, et al. Among authors: tortora g.
J Immunother Cancer. 2019 Apr 3;7(1):99. doi: 10.1186/s40425-019-0579-z.
J Immunother Cancer. 2019.
PMID: 30944023
Free PMC article.